Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 47XP4 | IM / RA |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y008119 | IM / LA |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | ES49H | IM / LA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | U8375AB | IM |
Nausea/ dizziness At approximately 0908, I began administering vaccines to a 17-year-old female patient. Prior to administration, I asked if the patient had eaten. Mother stated she had not. I offered the patient a snack prior to preparing the vaccines. A total of four vaccines were administered. Following the final dose (MenB), the patient became quiet and was unable to speak for approximately four seconds. I remained with the patient and instructed the mother to notify another nurse. I stood in front of the patient and observed pallor. The patient then verbalized feeling dizzy and nauseated. An emesis bag was provided; no emesis occurred. RN arrived with the emergency bag. Initial vitals obtained at 0915 were: T 98.5°F, HR 54?64, SpO2 99% on RA, BP 108/47. Vitals were monitored every five minutes with improvement noted. Final set of vitals: T 98.5°F, HR 62, SpO2 98%, BP 111/74. The patient was offered juice and stated she felt better. She reported experiencing cold sweats and nervousness following the MenB dose. RNs remained with the patient and provided education to the mother. Patient stated she felt well enough to go home. Recommended that patient remain home for the remainder of the day and continue to monitor for any further adverse effects. Injection sites were assessed post-vaccination. No signs of adverse reaction noted at this time. Will follow up with patient.
n/a
n/a
n/a
n/a